Mereo BioPharma Group plc (MREO) Misses Q2 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. HUM
2. SPCX
3. ALHC
4. PEP
5. T
6. SPY
7. CVS
8. UNH
9. DAL
10. TMUS

Go back to Mereo BioPharma Group plc (MREO) Misses Q2 EPS by 1c

Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 13, 2024 8:00 AM EDT

Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled

New long-term Phase 2 data from the Phase 2/3 Orbit study demonstrated continued reduction in fracture rates

Cash of $87.4 million as of June 30, 2024 expected to fund operations into 2027

LONDON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (Mereo or the Company), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the second quarter ended June 30, 2024, and provided an update on recent corporate... More